Get the Stockscreener App
4.30
0.92%
-0.04
After Hours:
4.26
-0.04
-0.93%
C 4 Therapeutics Inc stock is traded at $4.30, with a volume of 2.56M.
It is down -0.92% in the last 24 hours and down -0.92% over the past month.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
See More
Previous Close:
$4.34
Open:
$4.37
24h Volume:
2.56M
Relative Volume:
0.81
Market Cap:
$475.44M
Revenue:
$34.86M
Net Income/Loss:
$-103.80M
P/E Ratio:
-3.6305
EPS:
-1.1844
Net Cash Flow:
$-96.02M
1W Performance:
-2.27%
1M Performance:
-0.92%
6M Performance:
+122.80%
1Y Performance:
+182.89%
1-Day Range:
$4.15
$4.43
1-Week Range:
$4.125
$5.17
52-Week Range:
$1.435
$5.17
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
4.30 | 516.35M | 34.86M | -103.80M | -96.02M | -1.1844 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Initiated | TD Cowen | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Dec-19-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Equal-Weight |
| Jan-29-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-13-23 | Upgrade | Stifel | Hold → Buy |
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
Price to book forward of C4 Therapeutics, Inc. – NASDAQ:CCCC - TradingView
Price to earnings forward of C4 Therapeutics, Inc. – NASDAQ:CCCC - TradingView
Price to sales forward of C4 Therapeutics, Inc. – NASDAQ:CCCC - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
CCCC Stock Climbs As C4 Therapeutics Posts Strong Phase 1 Myeloma Data - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
[144] Candel Therapeutics, Inc. SEC Filing - Stock Titan
Director at vTv Therapeutics (VTVT) awarded 6,000 stock options grant - Stock Titan
C4 Therapeutics, Inc.(NasdaqGS: CCCC) added to Russell 2000 Index - marketscreener.com
C4 Therapeutics, Inc.(NasdaqGS: CCCC) added to Russell 2000 Value Benchmark - marketscreener.com
C4 Therapeutics, Inc.(NasdaqGS: CCCC) added to Russell 2500 Value Benchmark - marketscreener.com
Are medical stocks lagging C4 Therapeutics (CCCC) this year? - MSN
Form 4 C4 Therapeutics Inc For: 26 June By Investing.com - Investing.com Nigeria
C4 Therapeutics (NASDAQ: CCCC) director receives 62,000 stock options at $4.25 - Stock Titan
Director Steven Hoerter gets 62,000 C4 Therapeutics (CCCC) options at $4.25 - Stock Titan
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L. - Moomoo
Contineum Therapeutics (CTNM) awards director 19,000-share stock option grant - Stock Titan
Contineum Therapeutics (CTNM) elects Class II directors, ratifies Ernst & Young as 2026 auditor - Stock Titan
C4 Therapeutics (NASDAQ: CCCC) director receives grant of 62,000 stock options - Stock Titan
[Form 4] C4 Therapeutics, Inc. Insider Trading Activity - Stock Titan
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Anderson Kenneth Carl - Moomoo
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Director at C4 Therapeutics (CCCC) granted 62,000 stock options at $4.25 - Stock Titan
C4 Therapeutics (CCCC) director awarded 62,000 stock options at $4.25 strike - Stock Titan
C4 Therapeutics (CCCC) director receives 62,000-share stock option award - Stock Titan
C4 Therapeutics (CCCC) director receives grant of 62,000 stock options - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes - Stock Titan
CCCC Forecast — Price Target — Prediction for 2027 - TradingView
Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares - Stock Titan
C4 Therapeutics, Inc. Actuals & Estimates (NASDAQ:CCCC) - TradingView
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Morningstar
EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan
C4 Therapeutics Inc (CCCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
C4 Therapeutics Shareholders Back Directors, Pay and Auditors - TipRanks
Candel Therapeutics (CADL) director granted 32,000 stock options - Stock Titan
Candel Therapeutics (CADL) grants director 32,000 stock options at $9.08 - Stock Titan
C4 Therapeutics (NASDAQ: CCCC) investors approve directors, pay and stock plan change - Stock Titan
C4 Therapeutics (CCCC) AGM 2026 Summary - Quartr
C4 Therapeutics Inc (CCCC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Andrea Martin drives innovative science and mentorship at C4 Therapeutics, Inc. - Traders Union
Atrium Therapeutics awards stock grants to 8 new hires - Stock Titan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Inc (CCCC) Valuation: PE, PB & Fair Value Analysis - TradingKey
C4 Therapeutics Inc (CCCC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including CemsidomideSlideshow (NASDAQ:CCCC) 2026-06-20 - Seeking Alpha
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):